CRL is the official New York Stock Exchange ticker symbol for Charles River Laboratories International, Inc. The organization holds critical importance within the global healthcare and pharmaceutical ecosystem because it provides essential early-stage research models, preclinical discovery services, safety assessment testing, and manufacturing support that pharmaceutical companies rely on to advance novel therapeutics and life-saving drugs from the laboratory through clinical trials.
Charles River Laboratories is globally renowned as a premier provider of research models—most notably specialized laboratory rodents—and comprehensive preclinical contract research services.
Charles River Laboratories International is a massive, multi-billion-dollar global contract research organization and a prominent component of the S&P 500 index.
Charles River Laboratories demonstrates stable financial and operational performance, underscored by multi-billion-dollar annual revenues, robust client retention, and strategic expansions into cell and gene therapy manufacturing.
Charles River Laboratories is a premier contract research organization and a leading life sciences enterprise that provides essential early-stage drug discovery models, preclinical safety assessment services, and manufacturing solutions.
Investing in Charles River Laboratories (CRL) equity involves several inherent risks common to the life sciences and biopharmaceutical outsourcing sector.
Charles River Laboratories competes against several major contract research organizations (CROs) and specialized life sciences service providers operating within the global pharmaceutical outsourcing sector.
Charles River Laboratories is not owned by State Street Corporation, as it operates as an independent, publicly traded enterprise listed on the New York Stock Exchange.
The top institutional stock owners of Charles River Laboratories consist of massive global asset management firms that hold large equity stakes on behalf of mutual funds and index portfolios.
IQVIA was previously known as Quintiles Transnational Holdings Inc. before undergoing a massive merger with IMS Health Holdings.
The corporate net worth or market capitalization of Charles River Laboratories hovers around 13.5 billion US dollars, reflecting its total equity value on public stock exchanges.
Birgit Girshick serves as the Chief Executive Officer of Charles River Laboratories, having succeeded longtime executive James C. Foster.
Charles River Laboratories maintains a strong global reputation as a premier, highly trusted partner for biopharmaceutical corporations, academic institutions, and government agencies seeking reliable research models and preclinical development servi...
CRL is the official corporate ticker symbol for Charles River Laboratories International, Inc. on the New York Stock Exchange.
Equity research analysts and Wall Street financial institutions maintain generally favorable twelve-month consensus price targets for Charles River Laboratories (CRL) stock, driven by expected stabilization in biopharmaceutical outsourcing demand and...
Within the pharmaceutical, biotechnology, and regulatory sectors, CRL can refer to two distinct and prominent terms.
CRL stock represents the common equity shares of Charles River Laboratories International, Inc., which are publicly traded on the New York Stock Exchange and included as a constituent of the S&P 500 index.
Charles River Laboratories holds an official ranking among major corporate lists, having secured its position as a constituent of the S&P 500 index following years of consistent multi-billion-dollar revenue expansion.
Birgit Girshick serves as the Chief Executive Officer of Charles River Laboratories, having succeeded longtime executive James C. Foster following his planned retirement.
Charles River Laboratories International is a major multinational enterprise and a prominent component of the S&P 500 index, boasting multi-billion-dollar annual revenues.
Charles River Laboratories was founded in 1947 by Dr. Henry Foster, a young veterinarian who set up a small animal breeding operation in a second-floor loft in Boston overlooking the Charles River.
IQVIA has not acquired Charles River Laboratories, as both entities operate as independent publicly traded corporations within the global healthcare and pharmaceutical services sectors.
Charles River Laboratories generates robust annual consolidated revenues exceeding four billion US dollars.
Charles River Laboratories International, Inc. completed its initial public offering and began trading its common shares publicly on the New York Stock Exchange under the ticker symbol CRL in June 2000.
Within regulatory terminology utilized by the United States Food and Drug Administration, CRL stands for Complete Response Letter.
The core business model of Charles River Laboratories revolves around providing critical outsourced products and scientific services to the global healthcare and pharmaceutical industries.